Following the recommendation for regulatory approval under the European decentralized procedure, Toctino (alitretinoin) received national regulatory approval in Germany. Marketing applications for the use of alitretinoin in the
Under the agreement, Biolex will take full responsibility for development and commercialization of Locteron. OctoPlus will retain a royalty interest in the product candidate and provide manufacturing and
The company has announced that Richard Franklin, the company’s chairman, has assumed the newly-created position of executive chairman and Gere diZerega, one of the company’s clinical advisors, has
The grant will fund work over the next year to investigate whether the company’s proprietary human liver engrafting cells can be made resistant to infection by the hepatitis
Terms of the acquisition were not announced. The acquisition will not impact employees, vendors or customers, said Salvador Imaging. Mr Gardner said: “We see this as an extraordinary
Upon completion of the acquisition, China Biologic plans to re-open the additional plasma collection station in 2009. China Biologic intends to employ more advanced collection techniques at these
MethylGene expects to initiate a Phase I clinical trial in Canada in October 2008. The goal of this trial will be to assess the safety, pharmacokinetics and tolerability
XL888 is an orally available small molecule inhibitor of HSP90, which is a chaperone protein that promotes the activity and stability of a range of key regulatory proteins,
The study is designed to directly compare the effectiveness of Urgent PC treatment to non-active treatment. Uroplasty is undertaking this study primarily to support third-party reimbursement coverage. The
Interrad Medical has developed a completely new and innovative method for catheter securement called SecurAcath. The SecurAcath System utilizes a small anchor that deploys in the subcutaneous tissue
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.